Supply High Quality Orlistat Powder CAS 96829-58-2 Orlistat

• Powder: Yes
• Customized: Non-Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: HMJ-Orlistat
• Color: White
• Mf: C29h53no5
• Einecs: 639-755-1
• Molecular Weight: 495.73
• Test Method: HPLC
• CAS: 96829-58-2
• Shelf Life: 2 Years
• Grade: Pharmaceutical Grade
• Transport Package: Ziplock Foil Bag. Drum
• Specification: 1kg Per Foil Bag, 10 Bags Per Carton, 25 Kg Per Dr
• Trademark: HMJ
• Origin: China
• Production Capacity: 200kg/Month

Product Description

Supply High Quality Orlistat Powder CAS 96829-58-2 Orlistat 

Product Description

 

Product Name	Supply High Quality Orlistat Powder CAS 96829-58-2 Orlistat
Appearance	White powder
Molecular formula	C29H53NO5
Molecular weight	495.73
Keywords	Orlistat  , Material Orlistat ; Pure Orlistat
Shelf Life	24 months when properly stored
Storage	Keep in a cool, dry, dark location

Function

 

What is Orlistat ?

Orlistat is a product designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. Orlistat works by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested.

Orlistat blocks some of the fat that you eat, keeping it from being absorbed by your body.

Orlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. This medicine must be used together with a reduced-calorie diet. Orlistat is for use only in adults.

 

Function of Orlistat 
 

Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body mass.After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%).Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively). 

 

Detailed Photos

 

Related Product

Packaging & Shipping